Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHV Stock Price Chart Interactive Chart >
ACHV Price/Volume Stats
| Current price | $8.11 | 52-week high | $16.10 |
| Prev. close | $7.92 | 52-week low | $6.63 |
| Day low | $8.00 | Volume | 75,600 |
| Day high | $8.29 | Avg. volume | 220,145 |
| 50-day MA | $7.62 | Dividend yield | N/A |
| 200-day MA | $9.56 | Market Cap | 76.66M |
Achieve Life Sciences, Inc. (ACHV) Company Bio
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV News From Around the Web
Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences to Participate in Upcoming Investor ConferencesSEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021/ Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences. |
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual ConferenceSEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco (SRNT-E) Conference to be held virtually September 15-17, 2021. |
Achieve Life Sciences to Participate in Two Upcoming Investor ConferencesSEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will be participating in two upcoming investor conferences. |
ACHV: ORCA-2 Fully EnrolledBy John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter results in a press release and held a conference call after market close on August 12, 2021. The company concurrently filed its Form 10-Q with the SEC. Highlights for the second quarter ended June 30 th and to-date include: ➢ |
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement AwardsSEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics. |
ACHV Price Returns
| 1-mo | 12.02% |
| 3-mo | -2.17% |
| 6-mo | -31.50% |
| 1-year | -14.00% |
| 3-year | -83.71% |
| 5-year | -99.28% |
| YTD | 0.12% |
| 2020 | -23.57% |
| 2019 | -56.21% |
| 2018 | -90.97% |
| 2017 | -75.64% |
| 2016 | -58.68% |
Loading social stream, please wait...